Trade name: PREVNAR 13
Generic names: Pneumococcal 13-valent Conjugate Vaccine (Diphtheria CRM197 Protein) Suspension for intramuscular injection
Indication and Usage:
- In children 6 weeks through 5 years of age (prior to the 6th birthday):
- active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F.
- active immunization for the prevention of otitis media caused by S. pneumoniae serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F. No otitis media efficacy data are available for serotypes 1, 3, 5, 6A, 7F, and 19A.
- In children 6 years through 17 years of age (prior to the 18th birthday):
- active immunization for the prevention of invasive disease caused by S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F.
- In adults 18 years of age and older:
- active immunization for the prevention of pneumonia and invasive disease caused by S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F.
Ingredients: Each 0.5 mL dose of the vaccine is formulated to contain approximately 2.2 μg of each of Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F saccharides, 4.4 μg of 6B saccharides, 34 μg 26 CRM197 carrier protein, 100 μg polysorbate 80, 295 μg succinate buffer and 125 μg aluminum as aluminum phosphate adjuvant.
Manufacturer-listed adverse reactions | Pnuemococcal vaccine (Prevnar 13) can cause: Dermatitis (Eczema), Pruritus (Itchy skin), Uticaria (Hives), Lymphadenopathy, Cyanosis, Anaphylactic/anaphylactoid reaction including shock, Hypotonia, Angioneurotic edema, Apnea, Pallor (paleness).
Limitations of Effectiveness: Prevnar 13 does not protect against disease caused by S. pneumoniae serotypes that are not in the vaccine.
Need more info? Click the link below for a helpful infographic you can view + save on your device.
For product recommendations, please visit the Flu webpage.